Corti-Cut PM
90/100
This product looks safe
- Contains proprietary blend — exact ingredient amounts not disclosed
- 50% of ingredients have research evidence
A
Label Compliance Grade
Product Label
Have a supplement label? Find it here.
Upload a photo of any supplement label to search our database of 92,312 products.
Safety Alerts
ℹ️ Contains proprietary blend — exact ingredient amounts not disclosed
Label Data
2 Capsule(s)
Serving Size
30
Servings
Other Combinations
Product Type
50%
Evidence Coverage
Supplement Facts — Evidence Check
300 mg
📊 Market median: 500.0mg (223 products)
📚 22 studies (Tier A: 0, B: 1)
300 mg
📊 Market median: 500.0mg (143 products)
Proprietary Herbal Blend
200 mg
150 mg
📊 Market median: 500.0mg (861 products)
📚 60 studies (Tier A: 4, B: 13)
100 mg
📊 Market median: 200.0mg (358 products)
📚 9 studies (Tier A: 0, B: 2)
Phospholipids
100 mg
Other Ingredients
Gelatin
Rice Flour
Microcrystalline Cellulose
Ascorbyl Palmitate
Silica
Label Claims — Verification
❓
All Other
❓
Structure/Function
All Other (98% of products)
Structure/Function (78% of products)
Nutrient (56% of products)
Target Groups
Adult (18 - 50 Years)
Product Information
📋 Directions for Use
SUGGESTED USE: As a dietary supplement, take two (2) capsules before bed on an empty stomach, or as directed by a healthcare professional. For best results, use this product for at least eight weeks.
⚠️ Warnings & Precautions
WARNING: Do not take in conjunction with MAO inhibitor drugs. Not for use by persons with a history of malignant melanoma. Do not use if bipolar, pregnant, or lactating.
KEEP OUT OF REACH OF CHILDREN.
Additional Information
Corti-Cut PM may reduce cortisol levels to help diminish fat storage and preserve lean body tissue (metabolism).
Confused on what to take? Check yourself at: WhatVitaminsAreRightForYou.com
Made in USA
Nighttime Formula
STORE IN A COOL, DRY PLACE.
Since 1992 OL
Product Details
UPC / SKU
7 10013 03187 7
DSLD Entry Date
2012-06-25
Product Type
Other Combinations
Form
Capsule
Brand
OL Olympian Labs
DSLD ID
9512
Data Updated
2026-04-11
Research Evidence
50
Research Sources
47
Avg Quality Score
28
Rct
13
Clinical Trial
5
Guideline
4
Systematic Review
A
Using a Novel Consensus-Based Chemoinformatics Approach to Predict ADMET Properties and Druglikeness of Tyrosine Kinase Inhibitors.
B
Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors.
B
Branched-chain amino acid supplementation for improving growth and development in term and preterm neonates
B
[Clinical practice guideline on anaplastic lymphoma kinase-tyrosine kinase inhibitors for non-small cell lung cancer (2025 edition)].
B
[Chinese expert consensus on epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer (2025 edition)].
B
Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency.
B
Baseline-dependent effect of dopamine's precursor L-tyrosine on working memory gating but not updating
C
Attenuating Muscle Damage Biomarkers and Muscle Soreness After an Exercise-Induced Muscle Damage with Branched-Chain Amino Acid (BCAA) Supplementation: A Systematic Review and Meta-analysis with Meta-regression
Compare Similar Products
L-Tyrosine 500 mg
VitaCeutical Labs
100
Tyrosine
Vitabase
100
L-Tyrosine
Douglas Laboratories
100
L-Tyrosine 500 mg
Douglas Laboratories
100
N-Acetyl-L-Tyrosine 300
LifeLink
100